Kromax Group recently signed an exclusive agency agreement in Taiwan and mainland China with ElectroCore, Inc. (Nasdaq: ECOR), is a commercial stage bioelectronic medicine company dedicated to improving patient outcomes through its gammaCore^TM non-invasive vagus nerve stimulation therapy initially focused on the treatment of multiple conditions in neurology. This product is approved by the US FDA for the preventive treatment of cluster headaches and migraines, and acute treatment of migraines and cluster headaches. Recently, it has been authorized by the US FDA for emergency use to help COVID -19 patients can relieve their dyspnea symptoms. It is believed that after the product is marketed, it can bring greater help to patients in the current severe COVID-19 epidemic.

For more information, please visit: https://www.electrocore.com.